nodes	percent_of_prediction	percent_of_DWPC	metapath
Pramipexole—HTR1D—meninx—malignant glioma	0.0394	0.106	CbGeAlD
Pramipexole—HTR1B—dura mater—malignant glioma	0.0374	0.1	CbGeAlD
Pramipexole—HTR1D—dura mater—malignant glioma	0.0362	0.0973	CbGeAlD
Pramipexole—HTR2C—choroid plexus—malignant glioma	0.0305	0.0819	CbGeAlD
Pramipexole—DRD3—telencephalic ventricle—malignant glioma	0.0161	0.0431	CbGeAlD
Pramipexole—HTR2A—choroid plexus—malignant glioma	0.0153	0.0411	CbGeAlD
Pramipexole—DRD1—telencephalic ventricle—malignant glioma	0.0115	0.0309	CbGeAlD
Pramipexole—HTR1B—telencephalic ventricle—malignant glioma	0.00932	0.025	CbGeAlD
Pramipexole—HTR1D—telencephalic ventricle—malignant glioma	0.00902	0.0242	CbGeAlD
Pramipexole—HTR2C—telencephalic ventricle—malignant glioma	0.00894	0.024	CbGeAlD
Pramipexole—HTR2A—cerebellar cortex—malignant glioma	0.00771	0.0207	CbGeAlD
Pramipexole—HTR1A—telencephalic ventricle—malignant glioma	0.00752	0.0202	CbGeAlD
Pramipexole—DRD2—telencephalic ventricle—malignant glioma	0.0068	0.0183	CbGeAlD
Pramipexole—HTR2A—pons—malignant glioma	0.00545	0.0146	CbGeAlD
Pramipexole—HTR2A—vertebral column—malignant glioma	0.00541	0.0145	CbGeAlD
Pramipexole—HTR1B—blood vessel—malignant glioma	0.00461	0.0124	CbGeAlD
Pramipexole—HTR2A—telencephalic ventricle—malignant glioma	0.00448	0.012	CbGeAlD
Pramipexole—HTR1D—blood vessel—malignant glioma	0.00447	0.012	CbGeAlD
Pramipexole—HTR2A—pineal body—malignant glioma	0.00389	0.0104	CbGeAlD
Pramipexole—DRD5—telencephalon—malignant glioma	0.00362	0.00971	CbGeAlD
Pramipexole—Deep vein thrombosis—Temozolomide—malignant glioma	0.00325	0.00683	CcSEcCtD
Pramipexole—Oral candidiasis—Carmustine—malignant glioma	0.00322	0.00676	CcSEcCtD
Pramipexole—Aphasia—Carmustine—malignant glioma	0.00316	0.00663	CcSEcCtD
Pramipexole—Oral candidiasis—Temozolomide—malignant glioma	0.00312	0.00654	CcSEcCtD
Pramipexole—DRD1—brainstem—malignant glioma	0.00311	0.00836	CbGeAlD
Pramipexole—Embolism—Temozolomide—malignant glioma	0.00308	0.00647	CcSEcCtD
Pramipexole—Parosmia—Temozolomide—malignant glioma	0.00305	0.0064	CcSEcCtD
Pramipexole—Aphasia—Temozolomide—malignant glioma	0.00305	0.0064	CcSEcCtD
Pramipexole—Tooth disorder—Temozolomide—malignant glioma	0.00305	0.0064	CcSEcCtD
Pramipexole—Hypokinesia—Carmustine—malignant glioma	0.00303	0.00637	CcSEcCtD
Pramipexole—Paranoia—Carmustine—malignant glioma	0.003	0.0063	CcSEcCtD
Pramipexole—Thrombosis—Carmustine—malignant glioma	0.00289	0.00607	CcSEcCtD
Pramipexole—Myopathy—Temozolomide—malignant glioma	0.00282	0.00592	CcSEcCtD
Pramipexole—Apathy—Temozolomide—malignant glioma	0.00277	0.00581	CcSEcCtD
Pramipexole—DRD1—telencephalon—malignant glioma	0.00276	0.00742	CbGeAlD
Pramipexole—Flat affect—Temozolomide—malignant glioma	0.00275	0.00576	CcSEcCtD
Pramipexole—Stupor—Carmustine—malignant glioma	0.00274	0.00576	CcSEcCtD
Pramipexole—Scotoma—Carmustine—malignant glioma	0.0027	0.00566	CcSEcCtD
Pramipexole—Menorrhagia—Temozolomide—malignant glioma	0.00267	0.00561	CcSEcCtD
Pramipexole—Vaginal haemorrhage—Temozolomide—malignant glioma	0.00267	0.00561	CcSEcCtD
Pramipexole—Herpes zoster—Temozolomide—malignant glioma	0.00263	0.00551	CcSEcCtD
Pramipexole—Extrapyramidal disorder—Temozolomide—malignant glioma	0.00263	0.00551	CcSEcCtD
Pramipexole—Scotoma—Temozolomide—malignant glioma	0.00261	0.00547	CcSEcCtD
Pramipexole—Abscess—Carmustine—malignant glioma	0.00259	0.00543	CcSEcCtD
Pramipexole—Otitis media—Temozolomide—malignant glioma	0.00254	0.00533	CcSEcCtD
Pramipexole—HTR1B—brainstem—malignant glioma	0.00252	0.00677	CbGeAlD
Pramipexole—Memory impairment—Temozolomide—malignant glioma	0.00252	0.00529	CcSEcCtD
Pramipexole—Hyperaesthesia—Temozolomide—malignant glioma	0.00252	0.00529	CcSEcCtD
Pramipexole—DRD4—brain—malignant glioma	0.00248	0.00665	CbGeAlD
Pramipexole—HTR1D—brainstem—malignant glioma	0.00244	0.00656	CbGeAlD
Pramipexole—HTR2C—brainstem—malignant glioma	0.00242	0.00649	CbGeAlD
Pramipexole—HTR2A—endothelium—malignant glioma	0.00241	0.00646	CbGeAlD
Pramipexole—Petechiae—Temozolomide—malignant glioma	0.00241	0.00505	CcSEcCtD
Pramipexole—Endocrine disorder—Temozolomide—malignant glioma	0.00239	0.00501	CcSEcCtD
Pramipexole—Speech disorder—Carmustine—malignant glioma	0.00238	0.005	CcSEcCtD
Pramipexole—Accidental injury—Carmustine—malignant glioma	0.00231	0.00486	CcSEcCtD
Pramipexole—Speech disorder—Temozolomide—malignant glioma	0.0023	0.00483	CcSEcCtD
Pramipexole—Disturbance in attention—Temozolomide—malignant glioma	0.00228	0.00479	CcSEcCtD
Pramipexole—Breast pain—Temozolomide—malignant glioma	0.00227	0.00476	CcSEcCtD
Pramipexole—Amenorrhoea—Temozolomide—malignant glioma	0.00225	0.00473	CcSEcCtD
Pramipexole—HTR1B—telencephalon—malignant glioma	0.00224	0.00601	CbGeAlD
Pramipexole—HTR2A—blood vessel—malignant glioma	0.00222	0.00596	CbGeAlD
Pramipexole—DRD3—central nervous system—malignant glioma	0.00219	0.00589	CbGeAlD
Pramipexole—Viral infection—Temozolomide—malignant glioma	0.00219	0.0046	CcSEcCtD
Pramipexole—SLC22A1—telencephalon—malignant glioma	0.00219	0.00587	CbGeAlD
Pramipexole—Leukocytosis—Carmustine—malignant glioma	0.00218	0.00457	CcSEcCtD
Pramipexole—HTR1D—telencephalon—malignant glioma	0.00217	0.00582	CbGeAlD
Pramipexole—Herpes simplex—Temozolomide—malignant glioma	0.00215	0.00451	CcSEcCtD
Pramipexole—HTR2C—telencephalon—malignant glioma	0.00215	0.00576	CbGeAlD
Pramipexole—Gait disturbance—Carmustine—malignant glioma	0.0021	0.0044	CcSEcCtD
Pramipexole—Coordination abnormal—Carmustine—malignant glioma	0.00209	0.00438	CcSEcCtD
Pramipexole—Hearing impaired—Temozolomide—malignant glioma	0.00208	0.00436	CcSEcCtD
Pramipexole—Neck pain—Carmustine—malignant glioma	0.00207	0.00435	CcSEcCtD
Pramipexole—DRD5—central nervous system—malignant glioma	0.00205	0.00552	CbGeAlD
Pramipexole—Pulmonary embolism—Carmustine—malignant glioma	0.00205	0.0043	CcSEcCtD
Pramipexole—HTR1A—brainstem—malignant glioma	0.00204	0.00547	CbGeAlD
Pramipexole—Gait disturbance—Temozolomide—malignant glioma	0.00203	0.00425	CcSEcCtD
Pramipexole—HTR2B—telencephalon—malignant glioma	0.00202	0.00541	CbGeAlD
Pramipexole—Respiratory failure—Temozolomide—malignant glioma	0.00202	0.00423	CcSEcCtD
Pramipexole—Coordination abnormal—Temozolomide—malignant glioma	0.00202	0.00423	CcSEcCtD
Pramipexole—Musculoskeletal pain—Temozolomide—malignant glioma	0.002	0.0042	CcSEcCtD
Pramipexole—DRD1—midbrain—malignant glioma	0.00198	0.00533	CbGeAlD
Pramipexole—Pulmonary embolism—Temozolomide—malignant glioma	0.00198	0.00415	CcSEcCtD
Pramipexole—Depressed level of consciousness—Carmustine—malignant glioma	0.00198	0.00415	CcSEcCtD
Pramipexole—Urinary incontinence—Carmustine—malignant glioma	0.00198	0.00415	CcSEcCtD
Pramipexole—Candida infection—Carmustine—malignant glioma	0.00196	0.0041	CcSEcCtD
Pramipexole—Skin exfoliation—Carmustine—malignant glioma	0.00196	0.0041	CcSEcCtD
Pramipexole—Neuropathy—Carmustine—malignant glioma	0.00192	0.00403	CcSEcCtD
Pramipexole—Influenza like illness—Temozolomide—malignant glioma	0.00192	0.00403	CcSEcCtD
Pramipexole—Depressed level of consciousness—Temozolomide—malignant glioma	0.00191	0.00401	CcSEcCtD
Pramipexole—Urinary incontinence—Temozolomide—malignant glioma	0.00191	0.00401	CcSEcCtD
Pramipexole—Candida infection—Temozolomide—malignant glioma	0.00189	0.00396	CcSEcCtD
Pramipexole—Skin exfoliation—Temozolomide—malignant glioma	0.00189	0.00396	CcSEcCtD
Pramipexole—Coma—Carmustine—malignant glioma	0.00187	0.00393	CcSEcCtD
Pramipexole—Vaginal infection—Temozolomide—malignant glioma	0.00187	0.00392	CcSEcCtD
Pramipexole—Neuropathy—Temozolomide—malignant glioma	0.00186	0.0039	CcSEcCtD
Pramipexole—Neoplasm—Carmustine—malignant glioma	0.00185	0.00389	CcSEcCtD
Pramipexole—DRD2—brainstem—malignant glioma	0.00184	0.00494	CbGeAlD
Pramipexole—Gynaecomastia—Carmustine—malignant glioma	0.00183	0.00384	CcSEcCtD
Pramipexole—Dry eye—Temozolomide—malignant glioma	0.00183	0.00384	CcSEcCtD
Pramipexole—HTR1A—telencephalon—malignant glioma	0.00181	0.00485	CbGeAlD
Pramipexole—Neoplasm—Temozolomide—malignant glioma	0.00179	0.00375	CcSEcCtD
Pramipexole—Sepsis—Carmustine—malignant glioma	0.00178	0.00373	CcSEcCtD
Pramipexole—DRD2—retina—malignant glioma	0.00177	0.00476	CbGeAlD
Pramipexole—DRD3—brain—malignant glioma	0.00174	0.00468	CbGeAlD
Pramipexole—Phlebitis—Carmustine—malignant glioma	0.00173	0.00362	CcSEcCtD
Pramipexole—Thrombophlebitis—Carmustine—malignant glioma	0.00172	0.0036	CcSEcCtD
Pramipexole—Diabetes mellitus—Carmustine—malignant glioma	0.00171	0.00359	CcSEcCtD
Pramipexole—HTR2C—medulla oblongata—malignant glioma	0.00169	0.00453	CbGeAlD
Pramipexole—Ear pain—Temozolomide—malignant glioma	0.00168	0.00353	CcSEcCtD
Pramipexole—Thrombophlebitis—Temozolomide—malignant glioma	0.00166	0.00348	CcSEcCtD
Pramipexole—Eye pain—Carmustine—malignant glioma	0.00165	0.00346	CcSEcCtD
Pramipexole—DRD2—telencephalon—malignant glioma	0.00163	0.00438	CbGeAlD
Pramipexole—DRD5—brain—malignant glioma	0.00163	0.00438	CbGeAlD
Pramipexole—Gastroenteritis—Temozolomide—malignant glioma	0.00162	0.0034	CcSEcCtD
Pramipexole—Injury—Carmustine—malignant glioma	0.00162	0.00339	CcSEcCtD
Pramipexole—HTR1B—midbrain—malignant glioma	0.00161	0.00432	CbGeAlD
Pramipexole—Vascular purpura—Temozolomide—malignant glioma	0.00161	0.00337	CcSEcCtD
Pramipexole—Deafness—Temozolomide—malignant glioma	0.00161	0.00337	CcSEcCtD
Pramipexole—Eye pain—Temozolomide—malignant glioma	0.00159	0.00334	CcSEcCtD
Pramipexole—ADRA2C—telencephalon—malignant glioma	0.00159	0.00426	CbGeAlD
Pramipexole—Amnesia—Carmustine—malignant glioma	0.00158	0.00332	CcSEcCtD
Pramipexole—Nasal congestion—Temozolomide—malignant glioma	0.00158	0.00331	CcSEcCtD
Pramipexole—DRD1—central nervous system—malignant glioma	0.00157	0.00422	CbGeAlD
Pramipexole—HTR1B—spinal cord—malignant glioma	0.00157	0.00421	CbGeAlD
Pramipexole—HTR1D—midbrain—malignant glioma	0.00156	0.00418	CbGeAlD
Pramipexole—HTR2C—midbrain—malignant glioma	0.00154	0.00414	CbGeAlD
Pramipexole—Hot flush—Temozolomide—malignant glioma	0.00154	0.00322	CcSEcCtD
Pramipexole—Amnesia—Temozolomide—malignant glioma	0.00153	0.00321	CcSEcCtD
Pramipexole—Menopausal symptoms—Temozolomide—malignant glioma	0.00152	0.00319	CcSEcCtD
Pramipexole—Thirst—Temozolomide—malignant glioma	0.00151	0.00317	CcSEcCtD
Pramipexole—HTR2C—spinal cord—malignant glioma	0.0015	0.00404	CbGeAlD
Pramipexole—Hyponatraemia—Carmustine—malignant glioma	0.00149	0.00313	CcSEcCtD
Pramipexole—Purpura—Temozolomide—malignant glioma	0.00149	0.00313	CcSEcCtD
Pramipexole—Diplopia—Carmustine—malignant glioma	0.00149	0.00312	CcSEcCtD
Pramipexole—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.00149	0.00312	CcSEcCtD
Pramipexole—Diplopia—Temozolomide—malignant glioma	0.00144	0.00301	CcSEcCtD
Pramipexole—Face oedema—Carmustine—malignant glioma	0.00144	0.00301	CcSEcCtD
Pramipexole—Affect lability—Temozolomide—malignant glioma	0.00141	0.00297	CcSEcCtD
Pramipexole—Ataxia—Carmustine—malignant glioma	0.0014	0.00293	CcSEcCtD
Pramipexole—Face oedema—Temozolomide—malignant glioma	0.00139	0.00291	CcSEcCtD
Pramipexole—Mood swings—Temozolomide—malignant glioma	0.00136	0.00286	CcSEcCtD
Pramipexole—Hypokalaemia—Carmustine—malignant glioma	0.00135	0.00284	CcSEcCtD
Pramipexole—Ataxia—Temozolomide—malignant glioma	0.00135	0.00283	CcSEcCtD
Pramipexole—Dehydration—Temozolomide—malignant glioma	0.00134	0.0028	CcSEcCtD
Pramipexole—HTR2A—embryo—malignant glioma	0.00132	0.00355	CbGeAlD
Pramipexole—Dry skin—Temozolomide—malignant glioma	0.00132	0.00276	CcSEcCtD
Pramipexole—Muscular weakness—Carmustine—malignant glioma	0.00131	0.00275	CcSEcCtD
Pramipexole—Hypokalaemia—Temozolomide—malignant glioma	0.00131	0.00274	CcSEcCtD
Pramipexole—Breast disorder—Temozolomide—malignant glioma	0.0013	0.00272	CcSEcCtD
Pramipexole—HTR1A—midbrain—malignant glioma	0.0013	0.00348	CbGeAlD
Pramipexole—Dysphagia—Carmustine—malignant glioma	0.00128	0.0027	CcSEcCtD
Pramipexole—HTR1B—central nervous system—malignant glioma	0.00127	0.00342	CbGeAlD
Pramipexole—Muscular weakness—Temozolomide—malignant glioma	0.00127	0.00266	CcSEcCtD
Pramipexole—ADRA2A—telencephalon—malignant glioma	0.00127	0.0034	CbGeAlD
Pramipexole—HTR1A—spinal cord—malignant glioma	0.00127	0.0034	CbGeAlD
Pramipexole—Abdominal distension—Temozolomide—malignant glioma	0.00125	0.00262	CcSEcCtD
Pramipexole—ADRA2C—medulla oblongata—malignant glioma	0.00125	0.00335	CbGeAlD
Pramipexole—DRD1—brain—malignant glioma	0.00125	0.00335	CbGeAlD
Pramipexole—SLC22A1—central nervous system—malignant glioma	0.00124	0.00334	CbGeAlD
Pramipexole—Dysphagia—Temozolomide—malignant glioma	0.00124	0.00261	CcSEcCtD
Pramipexole—HTR1D—central nervous system—malignant glioma	0.00123	0.00331	CbGeAlD
Pramipexole—HTR2C—central nervous system—malignant glioma	0.00122	0.00328	CbGeAlD
Pramipexole—HTR2A—brainstem—malignant glioma	0.00121	0.00326	CbGeAlD
Pramipexole—Bronchitis—Temozolomide—malignant glioma	0.00119	0.00251	CcSEcCtD
Pramipexole—DRD2—midbrain—malignant glioma	0.00117	0.00315	CbGeAlD
Pramipexole—HTR2A—retina—malignant glioma	0.00117	0.00314	CbGeAlD
Pramipexole—Dysuria—Temozolomide—malignant glioma	0.00116	0.00244	CcSEcCtD
Pramipexole—Hyperglycaemia—Carmustine—malignant glioma	0.00116	0.00243	CcSEcCtD
Pramipexole—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00115	0.00242	CcSEcCtD
Pramipexole—Pneumonia—Carmustine—malignant glioma	0.00115	0.00242	CcSEcCtD
Pramipexole—Pollakiuria—Temozolomide—malignant glioma	0.00115	0.00241	CcSEcCtD
Pramipexole—HTR2B—central nervous system—malignant glioma	0.00115	0.00308	CbGeAlD
Pramipexole—Erectile dysfunction—Temozolomide—malignant glioma	0.00114	0.0024	CcSEcCtD
Pramipexole—Depression—Carmustine—malignant glioma	0.00114	0.0024	CcSEcCtD
Pramipexole—ADRA2C—midbrain—malignant glioma	0.00114	0.00306	CbGeAlD
Pramipexole—Photosensitivity reaction—Temozolomide—malignant glioma	0.00113	0.00238	CcSEcCtD
Pramipexole—Weight increased—Temozolomide—malignant glioma	0.00113	0.00237	CcSEcCtD
Pramipexole—Renal failure—Carmustine—malignant glioma	0.00113	0.00236	CcSEcCtD
Pramipexole—Weight decreased—Temozolomide—malignant glioma	0.00112	0.00236	CcSEcCtD
Pramipexole—Neuropathy peripheral—Carmustine—malignant glioma	0.00112	0.00236	CcSEcCtD
Pramipexole—Hyperglycaemia—Temozolomide—malignant glioma	0.00112	0.00235	CcSEcCtD
Pramipexole—Urinary tract infection—Carmustine—malignant glioma	0.00111	0.00234	CcSEcCtD
Pramipexole—Pneumonia—Temozolomide—malignant glioma	0.00111	0.00234	CcSEcCtD
Pramipexole—ADRA2C—spinal cord—malignant glioma	0.00111	0.00299	CbGeAlD
Pramipexole—Infestation—Temozolomide—malignant glioma	0.00111	0.00232	CcSEcCtD
Pramipexole—Infestation NOS—Temozolomide—malignant glioma	0.00111	0.00232	CcSEcCtD
Pramipexole—Depression—Temozolomide—malignant glioma	0.0011	0.00232	CcSEcCtD
Pramipexole—Neuropathy peripheral—Temozolomide—malignant glioma	0.00109	0.00228	CcSEcCtD
Pramipexole—HTR2A—telencephalon—malignant glioma	0.00108	0.00289	CbGeAlD
Pramipexole—Urinary tract infection—Temozolomide—malignant glioma	0.00108	0.00226	CcSEcCtD
Pramipexole—Hepatobiliary disease—Temozolomide—malignant glioma	0.00105	0.0022	CcSEcCtD
Pramipexole—Sinusitis—Temozolomide—malignant glioma	0.00104	0.00218	CcSEcCtD
Pramipexole—HTR1A—central nervous system—malignant glioma	0.00103	0.00276	CbGeAlD
Pramipexole—Hypoaesthesia—Carmustine—malignant glioma	0.00102	0.00215	CcSEcCtD
Pramipexole—Hallucination—Carmustine—malignant glioma	0.00102	0.00215	CcSEcCtD
Pramipexole—Oedema peripheral—Carmustine—malignant glioma	0.00101	0.00213	CcSEcCtD
Pramipexole—Connective tissue disorder—Carmustine—malignant glioma	0.00101	0.00212	CcSEcCtD
Pramipexole—HTR1B—brain—malignant glioma	0.00101	0.00271	CbGeAlD
Pramipexole—HTR1A—cerebellum—malignant glioma	0.001	0.00269	CbGeAlD
Pramipexole—ADRA2A—medulla oblongata—malignant glioma	0.000995	0.00267	CbGeAlD
Pramipexole—Visual impairment—Carmustine—malignant glioma	0.000991	0.00208	CcSEcCtD
Pramipexole—Hallucination—Temozolomide—malignant glioma	0.000989	0.00207	CcSEcCtD
Pramipexole—Hypoaesthesia—Temozolomide—malignant glioma	0.000989	0.00207	CcSEcCtD
Pramipexole—SLC22A1—brain—malignant glioma	0.000987	0.00265	CbGeAlD
Pramipexole—Pharyngitis—Temozolomide—malignant glioma	0.000986	0.00207	CcSEcCtD
Pramipexole—Urinary tract disorder—Temozolomide—malignant glioma	0.000981	0.00206	CcSEcCtD
Pramipexole—Oedema peripheral—Temozolomide—malignant glioma	0.000979	0.00205	CcSEcCtD
Pramipexole—HTR1D—brain—malignant glioma	0.000978	0.00263	CbGeAlD
Pramipexole—Connective tissue disorder—Temozolomide—malignant glioma	0.000977	0.00205	CcSEcCtD
Pramipexole—Urethral disorder—Temozolomide—malignant glioma	0.000974	0.00204	CcSEcCtD
Pramipexole—HTR2C—brain—malignant glioma	0.000968	0.0026	CbGeAlD
Pramipexole—Eye disorder—Carmustine—malignant glioma	0.000961	0.00202	CcSEcCtD
Pramipexole—Visual impairment—Temozolomide—malignant glioma	0.000958	0.00201	CcSEcCtD
Pramipexole—Flushing—Carmustine—malignant glioma	0.000954	0.002	CcSEcCtD
Pramipexole—Eye disorder—Temozolomide—malignant glioma	0.000929	0.00195	CcSEcCtD
Pramipexole—DRD2—central nervous system—malignant glioma	0.000928	0.00249	CbGeAlD
Pramipexole—Tinnitus—Temozolomide—malignant glioma	0.000927	0.00194	CcSEcCtD
Pramipexole—Flushing—Temozolomide—malignant glioma	0.000922	0.00194	CcSEcCtD
Pramipexole—Cardiac disorder—Temozolomide—malignant glioma	0.000922	0.00194	CcSEcCtD
Pramipexole—HTR2B—brain—malignant glioma	0.00091	0.00244	CbGeAlD
Pramipexole—ADRA2A—midbrain—malignant glioma	0.000909	0.00244	CbGeAlD
Pramipexole—Alopecia—Carmustine—malignant glioma	0.000909	0.00191	CcSEcCtD
Pramipexole—DRD2—cerebellum—malignant glioma	0.000907	0.00243	CbGeAlD
Pramipexole—ADRA2C—central nervous system—malignant glioma	0.000902	0.00242	CbGeAlD
Pramipexole—Angiopathy—Temozolomide—malignant glioma	0.000902	0.00189	CcSEcCtD
Pramipexole—Mental disorder—Carmustine—malignant glioma	0.000901	0.00189	CcSEcCtD
Pramipexole—Immune system disorder—Temozolomide—malignant glioma	0.000898	0.00188	CcSEcCtD
Pramipexole—Mediastinal disorder—Temozolomide—malignant glioma	0.000896	0.00188	CcSEcCtD
Pramipexole—Malnutrition—Carmustine—malignant glioma	0.000895	0.00188	CcSEcCtD
Pramipexole—Erythema—Carmustine—malignant glioma	0.000895	0.00188	CcSEcCtD
Pramipexole—Chills—Temozolomide—malignant glioma	0.000892	0.00187	CcSEcCtD
Pramipexole—ADRA2A—spinal cord—malignant glioma	0.000887	0.00238	CbGeAlD
Pramipexole—ADRA2C—cerebellum—malignant glioma	0.000881	0.00237	CbGeAlD
Pramipexole—Alopecia—Temozolomide—malignant glioma	0.000878	0.00184	CcSEcCtD
Pramipexole—Mental disorder—Temozolomide—malignant glioma	0.000871	0.00183	CcSEcCtD
Pramipexole—Back pain—Carmustine—malignant glioma	0.000866	0.00182	CcSEcCtD
Pramipexole—Erythema—Temozolomide—malignant glioma	0.000865	0.00182	CcSEcCtD
Pramipexole—Malnutrition—Temozolomide—malignant glioma	0.000865	0.00182	CcSEcCtD
Pramipexole—Dysgeusia—Temozolomide—malignant glioma	0.000847	0.00178	CcSEcCtD
Pramipexole—HTR2A—medulla oblongata—malignant glioma	0.000846	0.00227	CbGeAlD
Pramipexole—Vision blurred—Carmustine—malignant glioma	0.000844	0.00177	CcSEcCtD
Pramipexole—Tremor—Carmustine—malignant glioma	0.000839	0.00176	CcSEcCtD
Pramipexole—Back pain—Temozolomide—malignant glioma	0.000837	0.00176	CcSEcCtD
Pramipexole—Anaemia—Carmustine—malignant glioma	0.000827	0.00174	CcSEcCtD
Pramipexole—Agitation—Carmustine—malignant glioma	0.000823	0.00173	CcSEcCtD
Pramipexole—Vision blurred—Temozolomide—malignant glioma	0.000815	0.00171	CcSEcCtD
Pramipexole—HTR1A—brain—malignant glioma	0.000815	0.00219	CbGeAlD
Pramipexole—Tremor—Temozolomide—malignant glioma	0.000811	0.0017	CcSEcCtD
Pramipexole—Ill-defined disorder—Temozolomide—malignant glioma	0.000803	0.00168	CcSEcCtD
Pramipexole—Leukopenia—Carmustine—malignant glioma	0.000801	0.00168	CcSEcCtD
Pramipexole—Anaemia—Temozolomide—malignant glioma	0.0008	0.00168	CcSEcCtD
Pramipexole—Agitation—Temozolomide—malignant glioma	0.000795	0.00167	CcSEcCtD
Pramipexole—Malaise—Temozolomide—malignant glioma	0.00078	0.00164	CcSEcCtD
Pramipexole—Vertigo—Temozolomide—malignant glioma	0.000777	0.00163	CcSEcCtD
Pramipexole—Convulsion—Carmustine—malignant glioma	0.000776	0.00163	CcSEcCtD
Pramipexole—Leukopenia—Temozolomide—malignant glioma	0.000774	0.00162	CcSEcCtD
Pramipexole—HTR2A—midbrain—malignant glioma	0.000773	0.00208	CbGeAlD
Pramipexole—Hypertension—Carmustine—malignant glioma	0.000773	0.00162	CcSEcCtD
Pramipexole—Palpitations—Temozolomide—malignant glioma	0.000764	0.0016	CcSEcCtD
Pramipexole—Myalgia—Carmustine—malignant glioma	0.000762	0.0016	CcSEcCtD
Pramipexole—Chest pain—Carmustine—malignant glioma	0.000762	0.0016	CcSEcCtD
Pramipexole—Anxiety—Carmustine—malignant glioma	0.000759	0.00159	CcSEcCtD
Pramipexole—Cough—Temozolomide—malignant glioma	0.000755	0.00158	CcSEcCtD
Pramipexole—HTR2A—spinal cord—malignant glioma	0.000754	0.00203	CbGeAlD
Pramipexole—Convulsion—Temozolomide—malignant glioma	0.00075	0.00157	CcSEcCtD
Pramipexole—Hypertension—Temozolomide—malignant glioma	0.000747	0.00157	CcSEcCtD
Pramipexole—Confusional state—Carmustine—malignant glioma	0.000737	0.00155	CcSEcCtD
Pramipexole—Myalgia—Temozolomide—malignant glioma	0.000736	0.00155	CcSEcCtD
Pramipexole—Arthralgia—Temozolomide—malignant glioma	0.000736	0.00155	CcSEcCtD
Pramipexole—DRD2—brain—malignant glioma	0.000736	0.00198	CbGeAlD
Pramipexole—Anxiety—Temozolomide—malignant glioma	0.000734	0.00154	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000731	0.00153	CcSEcCtD
Pramipexole—Oedema—Carmustine—malignant glioma	0.000731	0.00153	CcSEcCtD
Pramipexole—Discomfort—Temozolomide—malignant glioma	0.000728	0.00153	CcSEcCtD
Pramipexole—Infection—Carmustine—malignant glioma	0.000726	0.00152	CcSEcCtD
Pramipexole—Dry mouth—Temozolomide—malignant glioma	0.00072	0.00151	CcSEcCtD
Pramipexole—ADRA2A—central nervous system—malignant glioma	0.00072	0.00193	CbGeAlD
Pramipexole—ADRA2C—brain—malignant glioma	0.000716	0.00192	CbGeAlD
Pramipexole—Thrombocytopenia—Carmustine—malignant glioma	0.000715	0.0015	CcSEcCtD
Pramipexole—Tachycardia—Carmustine—malignant glioma	0.000713	0.0015	CcSEcCtD
Pramipexole—Confusional state—Temozolomide—malignant glioma	0.000712	0.00149	CcSEcCtD
Pramipexole—Oedema—Temozolomide—malignant glioma	0.000706	0.00148	CcSEcCtD
Pramipexole—ADRA2A—cerebellum—malignant glioma	0.000703	0.00189	CbGeAlD
Pramipexole—Infection—Temozolomide—malignant glioma	0.000701	0.00147	CcSEcCtD
Pramipexole—Anorexia—Carmustine—malignant glioma	0.000696	0.00146	CcSEcCtD
Pramipexole—Nervous system disorder—Temozolomide—malignant glioma	0.000692	0.00145	CcSEcCtD
Pramipexole—Thrombocytopenia—Temozolomide—malignant glioma	0.000691	0.00145	CcSEcCtD
Pramipexole—Skin disorder—Temozolomide—malignant glioma	0.000686	0.00144	CcSEcCtD
Pramipexole—Hypotension—Carmustine—malignant glioma	0.000683	0.00143	CcSEcCtD
Pramipexole—Hyperhidrosis—Temozolomide—malignant glioma	0.000683	0.00143	CcSEcCtD
Pramipexole—Anorexia—Temozolomide—malignant glioma	0.000673	0.00141	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000666	0.0014	CcSEcCtD
Pramipexole—Insomnia—Carmustine—malignant glioma	0.000661	0.00139	CcSEcCtD
Pramipexole—Paraesthesia—Carmustine—malignant glioma	0.000656	0.00138	CcSEcCtD
Pramipexole—Dyspnoea—Carmustine—malignant glioma	0.000651	0.00137	CcSEcCtD
Pramipexole—Somnolence—Carmustine—malignant glioma	0.000649	0.00136	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000643	0.00135	CcSEcCtD
Pramipexole—Insomnia—Temozolomide—malignant glioma	0.000639	0.00134	CcSEcCtD
Pramipexole—Decreased appetite—Carmustine—malignant glioma	0.000635	0.00133	CcSEcCtD
Pramipexole—Paraesthesia—Temozolomide—malignant glioma	0.000634	0.00133	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Carmustine—malignant glioma	0.000631	0.00132	CcSEcCtD
Pramipexole—Dyspnoea—Temozolomide—malignant glioma	0.000629	0.00132	CcSEcCtD
Pramipexole—Somnolence—Temozolomide—malignant glioma	0.000628	0.00132	CcSEcCtD
Pramipexole—Pain—Carmustine—malignant glioma	0.000625	0.00131	CcSEcCtD
Pramipexole—Constipation—Carmustine—malignant glioma	0.000625	0.00131	CcSEcCtD
Pramipexole—Dyspepsia—Temozolomide—malignant glioma	0.000621	0.0013	CcSEcCtD
Pramipexole—Decreased appetite—Temozolomide—malignant glioma	0.000614	0.00129	CcSEcCtD
Pramipexole—HTR2A—central nervous system—malignant glioma	0.000612	0.00164	CbGeAlD
Pramipexole—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00061	0.00128	CcSEcCtD
Pramipexole—Fatigue—Temozolomide—malignant glioma	0.000609	0.00128	CcSEcCtD
Pramipexole—Constipation—Temozolomide—malignant glioma	0.000604	0.00127	CcSEcCtD
Pramipexole—Pain—Temozolomide—malignant glioma	0.000604	0.00127	CcSEcCtD
Pramipexole—Feeling abnormal—Carmustine—malignant glioma	0.000602	0.00126	CcSEcCtD
Pramipexole—HTR2A—cerebellum—malignant glioma	0.000598	0.00161	CbGeAlD
Pramipexole—Gastrointestinal pain—Carmustine—malignant glioma	0.000597	0.00125	CcSEcCtD
Pramipexole—Feeling abnormal—Temozolomide—malignant glioma	0.000582	0.00122	CcSEcCtD
Pramipexole—Abdominal pain—Carmustine—malignant glioma	0.000578	0.00121	CcSEcCtD
Pramipexole—Body temperature increased—Carmustine—malignant glioma	0.000578	0.00121	CcSEcCtD
Pramipexole—Gastrointestinal pain—Temozolomide—malignant glioma	0.000577	0.00121	CcSEcCtD
Pramipexole—ADRA2A—brain—malignant glioma	0.000571	0.00153	CbGeAlD
Pramipexole—Urticaria—Temozolomide—malignant glioma	0.000561	0.00118	CcSEcCtD
Pramipexole—Abdominal pain—Temozolomide—malignant glioma	0.000558	0.00117	CcSEcCtD
Pramipexole—Body temperature increased—Temozolomide—malignant glioma	0.000558	0.00117	CcSEcCtD
Pramipexole—Hypersensitivity—Carmustine—malignant glioma	0.000538	0.00113	CcSEcCtD
Pramipexole—Asthenia—Carmustine—malignant glioma	0.000524	0.0011	CcSEcCtD
Pramipexole—Hypersensitivity—Temozolomide—malignant glioma	0.00052	0.00109	CcSEcCtD
Pramipexole—Asthenia—Temozolomide—malignant glioma	0.000507	0.00106	CcSEcCtD
Pramipexole—Diarrhoea—Carmustine—malignant glioma	0.0005	0.00105	CcSEcCtD
Pramipexole—Pruritus—Temozolomide—malignant glioma	0.0005	0.00105	CcSEcCtD
Pramipexole—HTR2A—brain—malignant glioma	0.000486	0.0013	CbGeAlD
Pramipexole—Dizziness—Carmustine—malignant glioma	0.000483	0.00101	CcSEcCtD
Pramipexole—Diarrhoea—Temozolomide—malignant glioma	0.000483	0.00101	CcSEcCtD
Pramipexole—Dizziness—Temozolomide—malignant glioma	0.000467	0.00098	CcSEcCtD
Pramipexole—Vomiting—Carmustine—malignant glioma	0.000465	0.000975	CcSEcCtD
Pramipexole—Rash—Carmustine—malignant glioma	0.000461	0.000967	CcSEcCtD
Pramipexole—Dermatitis—Carmustine—malignant glioma	0.00046	0.000966	CcSEcCtD
Pramipexole—Headache—Carmustine—malignant glioma	0.000458	0.00096	CcSEcCtD
Pramipexole—Vomiting—Temozolomide—malignant glioma	0.000449	0.000942	CcSEcCtD
Pramipexole—Rash—Temozolomide—malignant glioma	0.000445	0.000934	CcSEcCtD
Pramipexole—Dermatitis—Temozolomide—malignant glioma	0.000445	0.000933	CcSEcCtD
Pramipexole—Headache—Temozolomide—malignant glioma	0.000442	0.000928	CcSEcCtD
Pramipexole—Nausea—Carmustine—malignant glioma	0.000434	0.000911	CcSEcCtD
Pramipexole—Nausea—Temozolomide—malignant glioma	0.000419	0.00088	CcSEcCtD
Pramipexole—DRD2—Signaling Pathways—BRAF—malignant glioma	1.53e-05	0.000101	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MMP9—malignant glioma	1.52e-05	0.000101	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—F2—malignant glioma	1.52e-05	0.000101	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—FN1—malignant glioma	1.52e-05	0.000101	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—CASP3—malignant glioma	1.52e-05	0.000101	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—PIK3CA—malignant glioma	1.52e-05	0.0001	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IL2—malignant glioma	1.52e-05	0.0001	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—PIK3CA—malignant glioma	1.52e-05	0.0001	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—PTEN—malignant glioma	1.51e-05	0.0001	CbGpPWpGaD
Pramipexole—DRD3—GPCR downstream signaling—AKT1—malignant glioma	1.51e-05	0.0001	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MDM2—malignant glioma	1.51e-05	0.0001	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—FGF2—malignant glioma	1.51e-05	9.99e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—RAF1—malignant glioma	1.51e-05	9.97e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—BRAF—malignant glioma	1.5e-05	9.96e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—BAD—malignant glioma	1.5e-05	9.95e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—CASP3—malignant glioma	1.5e-05	9.92e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IL2—malignant glioma	1.5e-05	9.9e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—ERBB2—malignant glioma	1.49e-05	9.87e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—NOTCH1—malignant glioma	1.49e-05	9.86e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—AKT2—malignant glioma	1.49e-05	9.85e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—VEGFA—malignant glioma	1.49e-05	9.84e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—EGFR—malignant glioma	1.48e-05	9.81e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—AKT1—malignant glioma	1.48e-05	9.77e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—STAT3—malignant glioma	1.47e-05	9.74e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—PIK3CB—malignant glioma	1.47e-05	9.74e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—TP53—malignant glioma	1.47e-05	9.7e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—PIK3CA—malignant glioma	1.47e-05	9.7e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—AKT2—malignant glioma	1.46e-05	9.7e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—PTEN—malignant glioma	1.46e-05	9.66e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MDM2—malignant glioma	1.46e-05	9.66e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CD80—malignant glioma	1.46e-05	9.66e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—EGFR—malignant glioma	1.46e-05	9.65e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—PIK3CA—malignant glioma	1.46e-05	9.65e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—APC—malignant glioma	1.46e-05	9.64e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CG—malignant glioma	1.46e-05	9.64e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—VEGFA—malignant glioma	1.45e-05	9.63e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—RAF1—malignant glioma	1.45e-05	9.63e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MDM2—malignant glioma	1.45e-05	9.61e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—RAF1—malignant glioma	1.45e-05	9.58e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—STAT3—malignant glioma	1.44e-05	9.54e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—EGF—malignant glioma	1.44e-05	9.53e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—ERBB2—malignant glioma	1.44e-05	9.52e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MMP9—malignant glioma	1.44e-05	9.5e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—VEGFA—malignant glioma	1.43e-05	9.48e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—ERBB2—malignant glioma	1.43e-05	9.48e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PTPN11—malignant glioma	1.43e-05	9.47e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PIK3CD—malignant glioma	1.43e-05	9.47e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—PTEN—malignant glioma	1.43e-05	9.45e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PIK3CB—malignant glioma	1.42e-05	9.4e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—PTEN—malignant glioma	1.42e-05	9.4e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—PIK3CA—malignant glioma	1.42e-05	9.39e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—STAT3—malignant glioma	1.42e-05	9.38e-05	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—PIK3CA—malignant glioma	1.42e-05	9.38e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MMP9—malignant glioma	1.42e-05	9.37e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CXCL8—malignant glioma	1.41e-05	9.36e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PIK3CB—malignant glioma	1.41e-05	9.35e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MDM2—malignant glioma	1.41e-05	9.35e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—PTEN—malignant glioma	1.41e-05	9.32e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PIK3CD—malignant glioma	1.41e-05	9.32e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—RAF1—malignant glioma	1.41e-05	9.32e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—KRAS—malignant glioma	1.4e-05	9.27e-05	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—PIK3CA—malignant glioma	1.39e-05	9.23e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—ERBB2—malignant glioma	1.39e-05	9.22e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—AKT1—malignant glioma	1.39e-05	9.21e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—KRAS—malignant glioma	1.38e-05	9.12e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PIK3CB—malignant glioma	1.37e-05	9.1e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—AKT1—malignant glioma	1.37e-05	9.09e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—FGF2—malignant glioma	1.37e-05	9.07e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—BRAF—malignant glioma	1.37e-05	9.06e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—MYC—malignant glioma	1.37e-05	9.05e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—VEGFA—malignant glioma	1.37e-05	9.05e-05	CbGpPWpGaD
Pramipexole—ADRA2B—GPCR downstream signaling—AKT1—malignant glioma	1.37e-05	9.04e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CXCL8—malignant glioma	1.36e-05	9.03e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—PTEN—malignant glioma	1.36e-05	9.01e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CXCL8—malignant glioma	1.36e-05	8.99e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—STAT3—malignant glioma	1.35e-05	8.96e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CASP3—malignant glioma	1.35e-05	8.96e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IL2—malignant glioma	1.35e-05	8.94e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—FGF2—malignant glioma	1.35e-05	8.92e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—MYC—malignant glioma	1.34e-05	8.86e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—EGFR—malignant glioma	1.34e-05	8.85e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PIK3CB—malignant glioma	1.33e-05	8.83e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—AKT2—malignant glioma	1.33e-05	8.82e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—EGFR—malignant glioma	1.33e-05	8.78e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PTGS2—malignant glioma	1.32e-05	8.75e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CXCL8—malignant glioma	1.32e-05	8.74e-05	CbGpPWpGaD
Pramipexole—HTR1A—GPCR downstream signaling—AKT1—malignant glioma	1.32e-05	8.73e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—MYC—malignant glioma	1.32e-05	8.72e-05	CbGpPWpGaD
Pramipexole—HTR2C—GPCR downstream signaling—AKT1—malignant glioma	1.31e-05	8.68e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—EGFR—malignant glioma	1.31e-05	8.67e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CASP3—malignant glioma	1.31e-05	8.65e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL2—malignant glioma	1.3e-05	8.63e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CASP3—malignant glioma	1.3e-05	8.6e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL2—malignant glioma	1.3e-05	8.59e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—VEGFA—malignant glioma	1.29e-05	8.53e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—EGFR—malignant glioma	1.29e-05	8.53e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—PIK3CA—malignant glioma	1.29e-05	8.52e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MDM2—malignant glioma	1.28e-05	8.48e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CD—malignant glioma	1.28e-05	8.48e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MMP9—malignant glioma	1.28e-05	8.46e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—RAF1—malignant glioma	1.28e-05	8.45e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—STAT3—malignant glioma	1.28e-05	8.45e-05	CbGpPWpGaD
Pramipexole—ADRA2C—GPCR downstream signaling—AKT1—malignant glioma	1.28e-05	8.44e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—VEGFA—malignant glioma	1.27e-05	8.42e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—PTEN—malignant glioma	1.27e-05	8.41e-05	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—PIK3CA—malignant glioma	1.27e-05	8.39e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—PIK3CA—malignant glioma	1.27e-05	8.38e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CASP3—malignant glioma	1.26e-05	8.37e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—ERBB2—malignant glioma	1.26e-05	8.36e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—KRAS—malignant glioma	1.26e-05	8.36e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL2—malignant glioma	1.26e-05	8.35e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MDM2—malignant glioma	1.26e-05	8.35e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—STAT3—malignant glioma	1.26e-05	8.33e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MYC—malignant glioma	1.26e-05	8.32e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—RAF1—malignant glioma	1.26e-05	8.32e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—KRAS—malignant glioma	1.25e-05	8.3e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PIK3CB—malignant glioma	1.25e-05	8.25e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—ERBB2—malignant glioma	1.24e-05	8.23e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—AKT1—malignant glioma	1.24e-05	8.21e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—AKT1—malignant glioma	1.24e-05	8.19e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—KRAS—malignant glioma	1.24e-05	8.19e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MMP9—malignant glioma	1.23e-05	8.17e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—EGFR—malignant glioma	1.23e-05	8.14e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MMP9—malignant glioma	1.23e-05	8.13e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PTEN—malignant glioma	1.23e-05	8.12e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PIK3CB—malignant glioma	1.23e-05	8.12e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—FGF2—malignant glioma	1.23e-05	8.12e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PTEN—malignant glioma	1.22e-05	8.08e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—KRAS—malignant glioma	1.22e-05	8.06e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CXCL8—malignant glioma	1.2e-05	7.93e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—AKT1—malignant glioma	1.2e-05	7.92e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MMP9—malignant glioma	1.19e-05	7.91e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—AKT1—malignant glioma	1.19e-05	7.88e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PTEN—malignant glioma	1.19e-05	7.86e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MYC—malignant glioma	1.19e-05	7.85e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CXCL8—malignant glioma	1.18e-05	7.8e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MYC—malignant glioma	1.17e-05	7.74e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—KRAS—malignant glioma	1.16e-05	7.69e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—PIK3CA—malignant glioma	1.16e-05	7.68e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—EGFR—malignant glioma	1.16e-05	7.68e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—AKT1—malignant glioma	1.16e-05	7.67e-05	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—AKT1—malignant glioma	1.16e-05	7.66e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PTEN—malignant glioma	1.15e-05	7.63e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—PIK3CA—malignant glioma	1.15e-05	7.62e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—VEGFA—malignant glioma	1.15e-05	7.6e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MDM2—malignant glioma	1.15e-05	7.59e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CASP3—malignant glioma	1.15e-05	7.59e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL2—malignant glioma	1.15e-05	7.58e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—EGFR—malignant glioma	1.14e-05	7.58e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—RAF1—malignant glioma	1.14e-05	7.57e-05	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—AKT1—malignant glioma	1.14e-05	7.54e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—STAT3—malignant glioma	1.14e-05	7.52e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—PIK3CA—malignant glioma	1.14e-05	7.52e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—ERBB2—malignant glioma	1.13e-05	7.49e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CASP3—malignant glioma	1.13e-05	7.47e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL2—malignant glioma	1.13e-05	7.46e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—TP53—malignant glioma	1.12e-05	7.43e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—PIK3CA—malignant glioma	1.12e-05	7.4e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CB—malignant glioma	1.12e-05	7.39e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—VEGFA—malignant glioma	1.11e-05	7.34e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—VEGFA—malignant glioma	1.1e-05	7.3e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TP53—malignant glioma	1.1e-05	7.28e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—STAT3—malignant glioma	1.1e-05	7.26e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—KRAS—malignant glioma	1.1e-05	7.25e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—STAT3—malignant glioma	1.09e-05	7.23e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MMP9—malignant glioma	1.08e-05	7.17e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TP53—malignant glioma	1.08e-05	7.16e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—KRAS—malignant glioma	1.08e-05	7.16e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PTEN—malignant glioma	1.08e-05	7.13e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CXCL8—malignant glioma	1.07e-05	7.1e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—VEGFA—malignant glioma	1.07e-05	7.1e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—PIK3CA—malignant glioma	1.07e-05	7.07e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MMP9—malignant glioma	1.07e-05	7.06e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—STAT3—malignant glioma	1.06e-05	7.03e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PTEN—malignant glioma	1.06e-05	7.02e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MYC—malignant glioma	1.06e-05	6.99e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—AKT1—malignant glioma	1.05e-05	6.96e-05	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—AKT1—malignant glioma	1.04e-05	6.86e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—AKT1—malignant glioma	1.03e-05	6.85e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—EGFR—malignant glioma	1.03e-05	6.84e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TP53—malignant glioma	1.03e-05	6.84e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—PIK3CA—malignant glioma	1.03e-05	6.82e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CASP3—malignant glioma	1.03e-05	6.79e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL2—malignant glioma	1.03e-05	6.78e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MYC—malignant glioma	1.02e-05	6.75e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MYC—malignant glioma	1.01e-05	6.71e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—PIK3CA—malignant glioma	1.01e-05	6.66e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—PIK3CA—malignant glioma	1e-05	6.63e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—EGFR—malignant glioma	9.97e-06	6.6e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—PIK3CA—malignant glioma	9.93e-06	6.57e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—EGFR—malignant glioma	9.92e-06	6.57e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MYC—malignant glioma	9.87e-06	6.53e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—KRAS—malignant glioma	9.76e-06	6.46e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TP53—malignant glioma	9.74e-06	6.45e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—VEGFA—malignant glioma	9.73e-06	6.44e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MMP9—malignant glioma	9.7e-06	6.42e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—EGFR—malignant glioma	9.65e-06	6.39e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PTEN—malignant glioma	9.64e-06	6.38e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—STAT3—malignant glioma	9.64e-06	6.38e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TP53—malignant glioma	9.61e-06	6.36e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—PIK3CA—malignant glioma	9.6e-06	6.35e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—VEGFA—malignant glioma	9.57e-06	6.34e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—STAT3—malignant glioma	9.48e-06	6.28e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—AKT1—malignant glioma	9.48e-06	6.28e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—KRAS—malignant glioma	9.42e-06	6.24e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—AKT1—malignant glioma	9.41e-06	6.23e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—KRAS—malignant glioma	9.37e-06	6.2e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—AKT1—malignant glioma	9.28e-06	6.14e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—AKT1—malignant glioma	9.14e-06	6.05e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—KRAS—malignant glioma	9.12e-06	6.03e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—PIK3CA—malignant glioma	8.97e-06	5.94e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MYC—malignant glioma	8.95e-06	5.93e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MYC—malignant glioma	8.81e-06	5.83e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—EGFR—malignant glioma	8.76e-06	5.8e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—AKT1—malignant glioma	8.72e-06	5.77e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—VEGFA—malignant glioma	8.71e-06	5.77e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TP53—malignant glioma	8.68e-06	5.74e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PIK3CA—malignant glioma	8.66e-06	5.73e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—STAT3—malignant glioma	8.63e-06	5.71e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—EGFR—malignant glioma	8.62e-06	5.7e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PIK3CA—malignant glioma	8.61e-06	5.7e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—AKT1—malignant glioma	8.41e-06	5.57e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PIK3CA—malignant glioma	8.38e-06	5.54e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TP53—malignant glioma	8.37e-06	5.54e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TP53—malignant glioma	8.33e-06	5.51e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—KRAS—malignant glioma	8.27e-06	5.48e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—AKT1—malignant glioma	8.22e-06	5.44e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—AKT1—malignant glioma	8.18e-06	5.42e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—KRAS—malignant glioma	8.14e-06	5.39e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PIK3CA—malignant glioma	8.14e-06	5.39e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—AKT1—malignant glioma	8.11e-06	5.37e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TP53—malignant glioma	8.1e-06	5.36e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MYC—malignant glioma	8.01e-06	5.3e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—AKT1—malignant glioma	7.84e-06	5.19e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—EGFR—malignant glioma	7.84e-06	5.19e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PIK3CA—malignant glioma	7.6e-06	5.03e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PIK3CA—malignant glioma	7.48e-06	4.95e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—KRAS—malignant glioma	7.41e-06	4.9e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TP53—malignant glioma	7.35e-06	4.87e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—AKT1—malignant glioma	7.33e-06	4.85e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TP53—malignant glioma	7.23e-06	4.79e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—AKT1—malignant glioma	7.07e-06	4.68e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—AKT1—malignant glioma	7.04e-06	4.66e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—AKT1—malignant glioma	6.84e-06	4.53e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CA—malignant glioma	6.8e-06	4.5e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—AKT1—malignant glioma	6.65e-06	4.4e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TP53—malignant glioma	6.58e-06	4.36e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—AKT1—malignant glioma	6.21e-06	4.11e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—AKT1—malignant glioma	6.11e-06	4.04e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—AKT1—malignant glioma	5.56e-06	3.68e-05	CbGpPWpGaD
